UPDATE: Citi Starts Clover Health (CLOV) at Buy

Citi analyst Ralph Giacobbe initiates coverage on Clover Health (NASDAQ: CLOV) with a Buy rating and a price target of $19.00.

The analyst comments "Clover is focused on the fast growing and under-penetrated Medicare market, leveraging its technology and data to create value for members, physicians, and government payors. The growth profile is attractive with multiple levers of opportunities in both existing and new markets, with direct contracting (DC) representing a new and untapped opportunity to further accelerate growth. Moreover, valuation may appear hefty on the surface, but when considering the growth profile, adjustments/factors related to DC, and comparable disruptive healthcare services companies, we see upside to current multiples."

For an analyst ratings summary and ratings history on Clover Health click here. For more ratings news on Clover Health click here.

Shares of Clover Health closed at $14.10 yesterday.

You May Also Be Interested In

• UPDATE: Citi Starts ConAgra (CAG) at Neutral
• UPDATE: Rosenblatt Starts Coinbase Global Inc. (COIN) at Buy, 'The Markets Have Spoken, Crypto is Here to Stay...'
• China Life Insurance Co. Ltd. (2628:HK) (LFC) PT Lowered to HK$22.86 at Nomura/Instinet